Real pricing, honest reviews, and evidence-based guidance for Indian patients navigating Ozempic, Wegovy, and Mounjaro — without the hype.
A new study analyzing more than 410,000 Reddit posts found that GLP-1 users frequently discuss side effects that may not be fully captured in clinical trials. Here's what the research discovered and what patients should know.
As GLP-1 adoption accelerates across India, a new model of obesity care is emerging. Rather than simply prescribing medication, companies and healthcare providers are building doctor-led ecosystems that combine diagnostics, monitoring, nutrition, and long-term support.
India's GLP-1 market has grown nearly tenfold in a year. While generic semaglutide has dramatically expanded access, Mounjaro continues to dominate sales. Here's what is driving the next phase of India's obesity-drug revolution.
For years, obesity drug companies competed on one metric: how much weight patients could lose. In 2026, the competition has shifted. The next generation of obesity drugs is being judged by long-term health benefits, convenience, affordability, and patient retention.
New research suggests GLP-1 drugs may do more than support weight loss. Scientists are investigating whether medications like semaglutide and tirzepatide can reduce cancer risk and slow the progression of certain obesity-related cancers.
Semaglutide · Novo Nordisk
Oral Semaglutide · Novo Nordisk
Tirzepatide · Eli Lilly
Semaglutide 2.4mg · Novo Nordisk